News Quantified

SPRO – spero therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy [Seeking Alpha]

Spero Therapeutics (NASDAQ:SPRO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Spero Therapeutics (NASDAQ:SPRO) was upgraded by analysts at Wall Street

-1.2%

BEAT

-17.3%

BEAT

-5.8%

BEAT

-10.9%

MISS

Form 8-K Spero Therapeutics, Inc. For: Mar 26

Form 10-K Spero Therapeutics, Inc. For: Dec 31

Form 4 Spero Therapeutics, Inc. For: Feb 06 Filed by: Rajavelu Esther

Form 4 Spero Therapeutics, Inc. For: Feb 06 Filed by: Keutzer Timothy

Form 4 Spero Therapeutics, Inc. For: Feb 02 Filed by: Keutzer Timothy

Top News Gainers

6/13 Spero Announces $10 Million Registered Direct Offering of Common Stock 22.4%

3/17 Spero Therapeutics Inc (NASDAQ: SPRO) had its price target lowered by analysts at Stifel Nicolaus from $22.00 to $21.00. They now have a "buy" rating on the stock. 21.5%

5/9 Q1/2019 3/31/2019 EPS -0.290 ZacksConsensus -0.760 ActVsEst 0.470 - Beat 11.5%

9/9 Spero Therapeutics Inc (NASDAQ: SPRO) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 11.0%

8/16 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%

6/17 Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference 5.8%

6/20 Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis 5.7%

9/10 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.4%

2/3 Form 4 Spero Therapeutics, Inc. For: Feb 03 Filed by: Keutzer Timothy 5.4%

10/16 Spero Therapeutics Inc (NASDAQ: SPRO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 4.9%

Top News Decliners

3/19 Form S-8 Spero Therapeutics, Inc. -26.1%

3/16 Form 10-K Spero Therapeutics, Inc. For: Dec 31 -18.7%

6/27 Spero Therapeutics Inc (NASDAQ: SPRO) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. -13.3%

3/11 Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection -11.9%

2/28 Form 8-K Spero Therapeutics, Inc. For: Feb 28 -7.8%

3/31 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.8%

4/30 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.3%

4/15 Spero Therapeutics Inc (NASDAQ: SPRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -4.4%

9/26 Spero Therapeutics Announces Presentations at IDWeek 2019 -4.1%

2/14 Form SC 13G/A Spero Therapeutics, Inc. Filed by: Aquilo Capital Management, LLC -4.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day